- Digital therapeutics, delivering evidence-based therapeutic interventions via software to prevent, manage, or treat medical conditions, are becoming increasingly essential in Europe’s evolving healthcare landscape due to their scalability, cost-effectiveness, and ability to support chronic disease management and behavioral health
- The rising demand for DTx is driven by the growing prevalence of chronic conditions such as diabetes, cardiovascular diseases, and mental health disorders, coupled with increasing acceptance of digital health tools among both patients and healthcare providers
- Germany dominated the Europe digital therapeutics (DTx) market with the largest revenue share of 31.7% in 2024, driven by its Digital Health Applications (DiGA) initiative that enables reimbursement for prescribed DTx, a supportive regulatory environment, and strong integration of digital therapeutics into clinical care pathways
- Spain is expected to be the fastest growing country in the Europe digital therapeutics (DTx) market during the forecast period, supported by national digital health initiatives, increased healthcare digitization, and growing demand for remote, patient-centric therapeutic solutions
- Solutions/Software segment dominated the Europe digital therapeutics (DTx) market with a market share of 65.2% in 2024, driven by its ease of deployment, scalability, and widespread use in managing chronic and behavioral health conditions through mobile apps and cloud-based platforms
